Roivant Sciences Ltd’s filing revealed that its President & Immunovant CEO Venker Eric unloaded Company’s shares for reported $1.71 million on Oct 09 ’25. In the deal valued at $16.30 per share,104,940 shares were sold. As a result of this transaction, Venker Eric now holds 1,504,959 shares worth roughly $24.68 million.
Then, Venker Eric sold 20,727 shares, generating $336,814 in total proceeds. Upon selling the shares at $16.25, the President & Immunovant CEO now owns 1,504,959 shares.
Before that, Venker Eric bought 20,727 shares. Roivant Sciences Ltd shares valued at $336,877 were divested by the Officer at a price of $16.25 per share.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Tuesday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 1.17% to $16.4. Over the last five days, the stock has gained 1.74%. Roivant Sciences Ltd shares have risen nearly 38.16% since the year began. Nevertheless, the stocks have risen 38.63% over the past one year.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-09-30, dropping by -11.08 million shares to a total of 27.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 39.05 million shares. There was a decline of -39.62%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
